ALK or ROS1-positive NSCLC
1 clinical trials · Condition
◉ Watch ALK or ROS1-positive NSCLC
| Record | Firm | Date |
|---|---|---|
| Long Term Safety Observation of Crizotinib in Chinese NSCLC Population (NCT03672643) | Pfizer | 2019-01-28 |
Track ALK or ROS1-positive NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.